IONS Ionis Pharmaceuticals Inc
Company Analysis
Latest News
🟢 Ionis Pharmaceuticals is trading 5% up in pre-market after FDA approves GSK’s hepatitis B treatment
Ionis Pharmaceuticals is trading at $46.70, up 5.49%, after partner GSK received FDA approval for Hibsago (bepirovirsen), a first-in-class treatment for...
Ionis' Partner GSK Receives FDA Approval for Hepatitis B Treatment HIBSAGO™
Ionis Pharmaceuticals announced that its partner, GSK, has received U.S. Food and Drug Administration (FDA) approval for HIBSAGO™ (bepirovirsen) for the...
🟢 Ionis Pharmaceuticals is trading 4.6% up in pre-market after FDA approval of Hibsago
Ionis Pharmaceuticals is trading 4.6% up at $47.49 before the October 21, 2026 market open after FDA approval of Hibsago (bepirovirsen). - FDA approved Hibsago...
🟢 Ionis Pharmaceuticals is trading 4% up amid biotech-sector rally
Ionis Pharmaceuticals is trading 4.02% up at $45.04 on October 9, 2026, alongside a biotech-sector rally; no clear company-specific announcement or catalyst...
🟢 Ionis Pharmaceuticals is trading 4.38% up — no clear catalyst identified
Ionis Pharmaceuticals is trading 4.38% higher at $46.45 on September 28, 2026; available reporting does not identify a cause. - Investor relations lists...
Ionis Pharmaceuticals maintains buy ratings, following successful ALS and kidney trials
Oppenheimer and H.C. Wainwright reiterated Outperform and Buy ratings for Ionis Pharmaceuticals on September 24, 2026. H.C. Wainwright maintained a $100 price...
Two Back-to-Back Phase 3 Wins Handed Ionis a 43% Rally — but Can a Royalty-Dependent Model Sustain the Surge?
Shares of Ionis Pharmaceuticals surged 43.3% to $62.96 on September 23, catapulting roughly $2.7 billion in market value onto a stock that had been languishing...
🟢 Ionis Pharmaceuticals is trading 43.3% up in after-hours trading after Sefaxersen met Phase 3 primary endpoint
Ionis Pharmaceuticals is trading at $62.96, up 43.32%, after Sefaxersen met its Phase 3 primary endpoint, significantly reducing proteinuria in IgA nephropathy...
🔴 Ionis Pharmaceuticals is trading 4.1% down today despite positive interim sefaxersen results
Ionis Pharmaceuticals is trading at $43.88 (-4.08%) on September 23, 2026, as broader risk-off trading and lingering Tryngolza launch concerns appear to weigh...
Ionis and Roche Report Positive Phase 3 Interim Results for Kidney Disease Drug Sefaxersen
Ionis Pharmaceuticals and its partner, Roche, announced positive prespecified interim results from the ongoing Phase 3 IMAgINATION study for their...
🟢 Ionis Pharmaceuticals is trading 4.3% up in pre-market; catalyst remains uncertain
Ionis Pharmaceuticals is trading 4.3% up in pre-market at $46.83, with no clear catalyst identified. - No new company-specific announcement was identified for...
🔴 Ionis Pharmaceuticals is trading 4.1% down today after pelacarsen’s failed Phase 3 cardiovascular-outcomes trial
Ionis Pharmaceuticals is trading 4.1% down at $44.84 as investors continue reassessing pelacarsen’s commercial and pipeline impact after its failed Phase 3...
🟢 Ionis Pharmaceuticals is trading 5% up today as biotech and major U.S. indexes rally
Ionis Pharmaceuticals is trading 4.96% up at $47.06, primarily as broader risk appetite lifts biotech and major U.S. indexes. - Rebounding after four...
🔴 Ionis Pharmaceuticals is trading 4% down today after pelacarsen’s Phase 3 cardiovascular endpoint failure
Ionis Pharmaceuticals is trading 4% down at $45.36 after investors continued reassessing partner Novartis’ September 4 announcement that pelacarsen’s Phase 3...
🔴 Ionis Pharmaceuticals is trading 4% down today after pelacarsen’s Phase 3 trial missed its cardiovascular endpoint
Ionis Pharmaceuticals is trading 4% down at $49.37 amid continued investor reassessment of partner Novartis’ September 4 announcement that pelacarsen’s Phase 3...
🔴 Ionis Pharmaceuticals is trading 4.2% down today after pelacarsen Phase 3 study misses primary cardiovascular endpoint
Ionis Pharmaceuticals is trading 4.2% down now at $51.96 as investors continue reassessing partner Novartis’ September 4 announcement that pelacarsen’s Phase 3...
California State Teachers Retirement System discloses massive 8,000% increase in Ionis stake
California State Teachers Retirement System (CalSTRS) has dramatically increased its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), according to a new...
Ionis Lost Its Biggest Bet on Heart Disease — Can Its Remaining Pipeline Justify the Stock?
Shares of Ionis Pharmaceuticals continued their slide Monday, trading at $53.73 — down 7.5% on the day and roughly 37% below their ~$86 level before the July 9...
🔴 Ionis Pharmaceuticals is trading 7.5% down today after pelacarsen trial failure compounds earlier setbacks
Ionis Pharmaceuticals is trading 7.5% down now at $53.73. This decline is primarily driven by the continued market reaction to the recent failure of the Phase...
🔴 Ionis Pharmaceuticals is trading 11.5% down in pre-market after CARDIO-TTRansform failed its primary endpoint
Ionis Pharmaceuticals is trading 11.5% down at $51.40, with the decline appearing to extend pressure from the July 9 announcement that the Phase 3...